Clinical Trial Update: An Open-Label Study of Zelboraf (Vemurafenib) in Patients With Braf V600 Mutation Positive Metastatic Melanoma [Phase 4]

View source ↗

Summary

Open-label Phase 4 trial evaluating vemurafenib in patients with BRAF V600 mutation-positive metastatic melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• Zelboraf (vemurafenib)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Malignant Melanoma | Phase 4 | Status: COMPLETED